Business Wire - December 3, 2007

The Aware(TM) HIV-1/2 OMT test was specifically designed to eliminate barriers to testing and encourage more people to get tested. The test is safe, highly accurate and non-invasive. Since no blood needs to be drawn, administration of the test eliminates the pain and discomfort, as well as safety concerns, associated with blood-based testing. The test is also easy to use, requiring little training and providing results in about 20 minutes.

"We are excited about the Aware(TM) HIV-1/2 OMT test now being available in Kenya," said Professor Alloys Orago, Director of the NACC. "This oral fluid test will encourage more people in Kenya to opt for getting tested for HIV."

"We are pleased to support the government of Kenya in the fight against HIV/AIDS with this donation," stated Dr. Guido Lippoli, Calypte's Director of Sales and Marketing. "In support of the Kenyan Government's emphasis on the importance of knowing your HIV status, each person being tested with the Aware(TM) HIV-1/2 OMT test will receive a blue 'I Am Aware' bracelet to wear with pride, demonstrating that they know their HIV status."

"In addition to being safe and non-invasive, the Aware(TM) HIV-1/2 OMT test is also cost effective," added Dr. Lippoli. "Everything needed to collect and test an oral fluid sample is included in the test kit. In contrast to conventional blood tests, no additional supplies such as syringes, lancets or needles are required. The Aware(TM) HIV-1/2 OMT test has an eighteen-month shelf life (1 1/2 year) and can be stored at room temperature. Calypte believes these attributes make Aware(TM) the only oral fluid HIV test on the market that can realistically support ongoing, high-volume oral fluid-based testing globally."

About Calypte Biomedical:

Calypte Biomedical Corporation (www.calypte.com) is a U.S.-based healthcare company focused on the development and commercialization of rapid testing products for sexually transmitted diseases such as the Aware(R) HIV-1/2 OMT test that are suitable for use at the point of care and at home. Calypte believes there is a significant need for rapid detection of such diseases globally to control their proliferation, particularly in developing countries, which lack the medical infrastructure to support laboratory-based testing. Calypte believes that testing for HIV and other sexually transmitted infectious diseases may make important contributions to public health, and could increase the likelihood of treating those with undetected HIV and other sexually transmitted diseases.

Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, the Company's ability to obtain additional financing, if and as needed, and access funds from its existing financing arrangements that will allow it to continue its current and future operations and whether demand for its test products in domestic and international markets will generate sufficient revenues to achieve positive cash flow and profitability. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities and Exchange Commission ("SEC"), including its annual report on Form 10-KSB for the year ended December 31, 2006 and its subsequent filings with the SEC.

Calypte Biomedical Corporation | Jerrold D. Dotson, jdotson@calypte.com | VP-Finance, 503-726-2227

or

Investor Relations: CEOcast, Inc. | Andrew Hellman, adhellman@ceocast.com | 212-732-4300

071203
BW071201

Copyright © 2007 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.

Always watch for outdated information. This article first appeared in 2007. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2007. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .